| Literature DB >> 31909166 |
Sally E Hayward1,2, Jennifer B Dowd3, Helen Fletcher4, Laura B Nellums2,5, Fatima Wurie6, Delia Boccia1.
Abstract
BACKGROUND: Tuberculosis (TB) remains an urgent global public health priority, causing 1.5 million deaths worldwide in 2018. There is evidence that psychosocial factors modulate immune function; however, how this may influence TB risk or BCG vaccine response, and whether this pathway can be modified through social protection, has not been investigated. This paper aims to: a) systematically review evidence of how psychosocial factors influence the expression of biomarkers of immunity, and b) apply this general evidence to propose plausible TB-specific pathways for future study.Entities:
Keywords: BCG vaccine; Immunity; Psychosocial; Social protection; Stress; Tuberculosis
Year: 2019 PMID: 31909166 PMCID: PMC6939020 DOI: 10.1016/j.ssmph.2019.100522
Source DB: PubMed Journal: SSM Popul Health ISSN: 2352-8273
Fig. 1Conceptual framework. This conceptual framework depicts several pathways through which social protection interventions may affect TB outcomes. ‘TB outcomes’ here includes TB exposure, infection, disease, and adverse outcomes. In this paper we focus on the pathway linking psychosocial factors with biomarkers of immunity (orange boxes in the figure) and apply the findings to the context of TB. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
Inclusion criteria.
| Population | Any age group in any geographic location Exclude HIV-infected populations |
| Exposure | Psychosocial factors Defined by psychosocial exposure or perception thereof, rather than solely the physiological response Precedes onset of infectious disease (although include cross-sectional studies where directionality is unclear) Exclude ‘extreme’ stressors |
| Control | Level of psychosocial factor (e.g. stress level), or no psychosocial factor (e.g. no childhood abuse) |
| Outcome | Biomarkers of immunity Restrict to studies relating to infectious disease Include vaccine response |
| Study design | Original epidemiological studies Exclude protocols, case reports (sample size must be >2), abstracts and conferences Exclude commentaries and reviews Exclude laboratory and animal studies |
Fig. 2Flow chart of literature search. Adapted from PRISMA 2009 Flow Diagram (Moher, Liberati, Tetzlaff, Altman, & The Prisma Group, 2009). 107 articles were excluded following full-text screening because they did not meet the inclusion criteria. The most common reasons for exclusion at this stage were: HIV-infected population, ‘extreme’ stressor, onset of infection precedes psychosocial stressor, and not relating to infectious disease.
Fig. 3Summary of vaccine response studies.
Fig. 4Summary of herpesviruses studies.
Fig. 5Summary of other infectious disease studies.
| Data Extraction | Critical Appraisal | |
|---|---|---|
| First author | ||
| Year | ||
| Title | ||
| Population | ||
| Setting | ||
| Sampling method | ||
| Inclusion/exclusion criteria | ||
| Sample size | ||
| Response rate | ||
| Sample characteristics | ||
| Aim of study | ||
| Study design | ||
| Description of methods | ||
| Duration of follow-up (if relevant) | ||
| Loss to follow-up (if relevant) | ||
| Statistical methods used | ||
| Exposure variables (psychosocial factors) | ||
| Measurement of exposure | ||
| Outcome variables (biomarkers of immunity) | ||
| Measurement of outcome | ||
| Mediator variables | ||
| Measurement of mediators | ||
| Confounder variables | ||
| Measurement of confounders | ||
| Application to infectious disease | ||
| Strength of findings (none, weak, mixed, strong) | ||
| Key findings | ||
| Key conclusions of authors | ||
| Study quality overall judgement: high/moderate/low | ||
| Other comments | ||